Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Prostate. 2015 Aug 7;75(15):1718–1725. doi: 10.1002/pros.23053

Table III.

Mean LINE-1 and Alu DNA methylation levels and prostate cancer risk by time from blood draw to diagnosis for the cases

Controlsa Cases
DNA methylation marker quartilesb < 2 yearsc 2 to < 3 years 3 to <4 years ≥ 4 years pheterogeneityd,e
LINE-1 f
Quartile Range n n OR (95% CI)e n OR (95% CI)e n OR (95% CI)e n OR (95% CI)e
Q1 63.3-73.0 182 53 REF 41 REF 38 REF 39 REF
Q2 >73.0-74.1 178 39 0.75 (0.46-1.20) 50 1.22 (0.75-1.98) 60 1.83 (1.13-2.98) 39 1.07 (0.64-1.79)
Q3 >74.1-75.3 177 72 1.30 (0.84-2.00) 41 0.98 (0.59-1.63) 37 1.06 (0.62-1.80) 35 1.00 (0.59-1.68)
Q4 >75.3-82.9 163 54 1.04 (0.66-1.64) 32 0.91 (0.53-1.55) 26 0.88 (0.49-1.57) 35 1.18 (0.70-1.99) 0.83
ptrendg 0.43 0.60 0.40 0.62
Alu f
Q1 20.5-24.6 175 82 REF 40 REF 35 REF 21 REF
Q2 >24.6-25.7 199 65 0.71 (0.47-1.06) 46 1.13 (0.69-1.86) 42 1.15 (0.68-1.94) 39 1.80 (1.01-3.21)
Q3 >25.7-26.3 162 41 0.50 (0.32-0.78) 39 1.08 (0.65-1.81) 48 1.39 (0.83-2.35) 41 1.90 (1.06-3.41)
Q4 >26.3-29.1 163 31 0.40 (0.25-0.65) 39 1.13 (0.67-1.90) 37 1.22 (0.71-2.07) 44 2.26 (1.27-4.00) 5.3×10−6
ptrendg 3.8×10−5 0.64 0.32 4.4×10−3
a

Comparison group

b

Defined among controls

c

Prostate cancer cases diagnosed less than one year after blood draw were excluded in the study design

d

P-value for heterogeneity from Wald Chi-square test comparing effects of Q4 (vs. Q1) on the four case groups relative to controls

e

Adjusted for age at blood draw, year of blood draw, family history of prostate cancer (yes/possible, no), smoking status (never, former, current, pipe/cigar), total folate intake (quartiles), and BMI (<25, 25-29, 30 or higher)

f

Average across positions 1-4

g

Based on a variable assigned the median value (among controls) for each quartile entered as a continuous variable in the model